Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

eatment periods. Adverse events were generally of mild to moderate severity and occurred in all three treatment groups and the placebo group. The frequency of adverse events was dose-ordered across the 10 mg, 15 mg and 20 mg doses, with the 20 mg group reporting the highest number of events. There were few reports of gastrointestinal complaints in any of the three dose groups.

About Xerostomia

Xerostomia, or dry mouth, is the result of decreased salivary flow and is a symptom of a number of underlying conditions. Causes of dry mouth include Sjogren's syndrome; radiation treatment to the head and neck; and HIV-related salivary gland disease. Xerostomia can also be a side effect of medications and is associated with aging.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions, including statements regarding the potential of NGX267 as a treatment for xerostomia, the potential of NGX267 to treat xerostomia associated with Sjogren's syndrome, radiation treatment to the head and neck, HIV-related salivary gland disease, aging, or side effects of medication, and the potential t
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , September 12, 2014 ... Market by Application [Beverages (Alcoholic, CSD, Sports & Energy ... Pet Food, Meat & Seafood)], by Material (Aluminum ... by MarketsandMarkets, defines and segments the Food & ... of each application in terms of volumes and ...
(Date:9/12/2014)... , Sept. 12, 2014 /PRNewswire-iReach/ -- 9 th ... 22-24, 2014 – Bethesda, MD ... http://www.fdanews.com/9thInspectionsSummitEarlyBird   Photo - http://photos.prnewswire.com/prnh/20140912/145652 ... for the next inspection than to get a glimpse ... during and after an inspection. Come to ...
(Date:9/12/2014)... 12, 2014 Research and Markets ... "Global Medical Technologies Market 2014-2018" report to ... a collective term for software solutions, medical devices, ... health. The Global Medical Technologies market covers active ... In vitro diagnostics technology, dental technology, electromechanical medical ...
Breaking Medicine Technology:Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 2Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 3Food & Beverage Metal Cans Market Worth $49.20 Billion by 2019 4FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 2FDAnews Announces: Early Bird Registration Discount Ends Sept.19 for 9th Annual Inspections Summit, Oct. 22-24, 2014 3Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 2Global Medical Technologies Market 2014-2018: Key Vendors are GE, Johnson & Johnson, Medtronic, Roche and Siemens 3
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
(Date:9/15/2014)... Greenbelt, MD (PRWEB) September 15, 2014 With ... for Vascular Medicine can gain valuable insight to help personalize ... artery disease (PAD) . , The ideal approach to medicine ... doctor to predict how a patient will respond to specific ... identify a patient’s genetic makeup, allowing the physician to tailor ...
(Date:9/15/2014)... September 15, 2014 Marlton, New Jersey, ... , Stuart M. Goldstein, of the law firm of ... in obtaining the issuance of U.S. Patent No. 8,774,911 ... patent’s medically innovative design for a pedicle locator instrument ... New Jersey, a board certified neurosurgeon specializing in minimally-invasive ...
(Date:9/15/2014)... Aliso Viejo, California (PRWEB) September 15, 2014 ... themes and 3rd party plugins have announced a new Template ... is to offer our users a wide variety quality themes ... to our growing library," says Christian Austin, Pixel Film Studios ... our users will love.” , Qube features intuitive controls that ...
(Date:9/15/2014)... 2014 Fancyflyingfox.com, the distinguished wedding dress ... for beach wedding dresses . All clients can ... company’s website, up to 70 percent off. According to ... to all its loyal customers by launching the current ... more than 300 different styles of special occasion gowns ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Concox ... tracker and wireless communications equipment, is dedicated to bringing ... world. , Being the best-seller in Concox’s products, GT06N ... appealing to customers. GT06N is a mini and original ... It can be installed in the shelters on cars ...
Breaking Medicine News(10 mins):Health News:Center for Vascular Medicine Offers Genetic Testing For Personalized Vascular Care 2Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 2Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 3Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 4Health News:Patent Attorney Stuart M. Goldstein Helps Client Receive a Patent on a Surgical Device designed to Increase Accuracy and Safety in Vertebrae Repair and Attachment 5Health News:Announcing the Release of a New Template for Final Cut Pro X, The Qube Theme from Pixel Film Studios 2Health News:Great Discounts On Beach Wedding Dresses Announced By Fancyflyingfox.com Now 2Health News:iConcox GPS Vehicle Tracker GT06N Designed for Customers' Security 2
... versus Caucasian men when it comes to prostate cancer ... in African Americans, it is often more aggressive and ... social and biological factors influencing disparities among African-American men ... Research conference on The Science of Cancer Health Disparities ...
... make it tougher for them to function socially, study ... diagnosed with autism have more gray matter in their ... novel imaging technique to analyze brain structure. , The ... it harder for autistic children to learn how to ...
... Stress can ruin your whole day,... and your whole ... Americans annually suffer from occasional sleeplessness, and the,stress of ... and sleep are not comfortable bed partners," explains Cheryl,Myers, ... "But,many people don,t recognize that stress may be the ...
... Medicine Group Dr. Nicholas M., Halikis ... Systems., REDONDO BEACH, Calif., Nov. 28 ... to healthcare providers,today announced the election of Nicholas ... Dr. Halikis joins a distinguished Board that ...
... solution developed in response to evidence-based recommendations ... on improving drug labels, PHILADELPHIA, Nov. 28 You ... the container label says: "take one,tablet by mouth twice daily ... your medicine? This might be easy for you to answer, ...
... genX International, Inc and,IVFonline, LLC (genX ... products are being sold to some IVF ... distributed by genX International,and IVFonline. Therefore, genX ... Coda(R) products and genX International cannot,guarantee that ...
Cached Medicine News:Health News:Genetic and behavioral differences add to prostate cancer disparities 2Health News:Genetic and behavioral differences add to prostate cancer disparities 3Health News:Genetic and behavioral differences add to prostate cancer disparities 4Health News:Genetic and behavioral differences add to prostate cancer disparities 5Health News:Autistic Children Have More Gray Matter in Brains 2Health News:Autistic Children Have More Gray Matter in Brains 3Health News:Autistic Children Have More Gray Matter in Brains 4Health News:Reduce Stress Hormones to Beat Sleep Problems 2Health News:Prominent Orthopaedic Hand and Upper Extremity Surgeon Joins Radlink Board of Directors 2Health News:System of Simplified, Standardized Dosing Instructions for Prescription Medication Container Labels Proposed at Sixth Annual National Health Communication Conference 2Health News:System of Simplified, Standardized Dosing Instructions for Prescription Medication Container Labels Proposed at Sixth Annual National Health Communication Conference 3Health News:Warning - Beware of Counterfeit Coda(R) Products 2
... PoliPhase® is a biologically based ... two component system consisting of a ... the control of internal bleeding. ... readily flow on to a prepared ...
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
... DERMABOND* Topical Skin Adhesive gives you ... adhesive is intended for topical application only ... of wounds from surgical incisions, including punctures ... cleansed, trauma-induced lacerations. DERMABOND adhesive may be ...
... BD Cell-Tak™ Cell and Tissue Adhesive is ... Mytilus edulis (marine mussel). These proteins are ... by the mussel to anchor itself to ... Cell-Tak Cell and Tissue Adhesive is used ...
Medicine Products: